Actionable news
All posts from Actionable news
Actionable news in XBIT: XBiotech Inc,

XBiotech Appoints Amgen Veteran Scott Whitehurst as Chief Financial Officer

AUSTIN, Texas, May 03, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (XBIT), developer of True Human™ therapeutic antibodies, announced the appointment of Scott Whitehurst as Chief Financial Officer, effective today. He will oversee the Company’s financial operations, capital requirements and investor relations function, reporting to John Simard, XBiotech Founder, Chairman and Chief Executive Officer.

Whitehurst brings to XBiotech more than 25 years of international business and finance experience in the biotechnology and technology industries.

“We are pleased to welcome Scott to the XBiotech team during what is a particularly exciting time for the Company,” Simard said. “His breadth of experience in corporate finance, operations and strategic transactions is well suited to helping XBiotech advance towards commercialization and further expand and develop our commercial opportunities for novel antibody therapies.”

Whitehurst joins XBiotech from Amgen, where he served as Vice President of Finance, Operations, for the past eight years. While at Amgen, he was instrumental in developing and implementing a strategy to optimize Amgen’s manufacturing network and supply chain and in creating Amgen’s Global Business Services unit. He also served as Chief Financial Officer of Novartis Animal Health in Basel, Switzerland. Prior to his time at Novartis, Whitehurst spent 14 years at the Hewlett-Packard Co. in various financial management positions throughout the world, ultimately becoming Vice President of Finance responsible for some of the company's largest divisions, regions and acquisitions.

“I am delighted to join the XBiotech team in supporting the development of highly...